The first ever gene therapy for HAE is now ‘one step closer’, with the manufacturer confirming that the US FDA has accepted a license application for lonvo-z, and an initial decision is expected by March 2027. If approved, HAE would become the first condition in the world where a therapy based on CRISPR-based gene-editing takes place inside the body.

John Leonard MD, President and Chief Executive Officer of the manufacturer, Intellia Therapeutics, said: “Today marks an important milestone for the patients we are committed to serving and for Intellia’s pioneering work in the field of in vivo gene editing. Backed by compelling Phase 3 data, we believe lonvo-z could fundamentally change the way HAE is treated and are excited by its potential to become the world’s first approved in vivo CRISPR-based therapy. With the FDA’s Priority Review underway, our team is well prepared to deliver this one-time treatment to patients who are waiting for new options.”

Dr Joshua Jacobs, MD, Medical Director, Allergy and Asthma Clinical Research, Inc, and part of the clinical trials of lonvo-z, commented: “Today’s announcement is exciting because it advances us one step closer to potentially having a one-time treatment option available for patients who continue to be burdened by this chronic disease.”

(Source: Intellia Therapeutics)